Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dose Finding At Breakthrough Speed: FDA Found A Role For Anecdotal Reports On Zykadia

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Review of Novartis’ lung cancer therapy highlights the difficulties of getting traditional dosing work done in the compressed development program of a “breakthrough” drug – and shows just how flexible the agency will be in gathering information for the accelerated programs.

You may also be interested in...



Zykadia Expedited Timeline Challenged By Late-Breaking GMP Concern

CDER Director Woodcock was quickly consulted about a manufacturing concern at a foreign site that emerged shortly before FDA’s target action date for Novartis’ ceritinib NDA as the agency strove to avoid delaying approval of the “breakthrough” lung cancer therapy.

Novartis’ Zykadia Sets New “Breakthrough” Speed Record For NME Review

FDA grants accelerated approval to ceritinib following a four-month review. The ALK inhibitor is indicated for non-small cell lung cancer patients who have progressed on or are intolerant of Pfizer’s Xalkori.

Expanded Access Opens Window For Dose Optimization Studies In Cancer

The period after completion of pivotal trials but ahead of FDA approval provides an opportunity for oncology drug sponsors to conduct badly needed dose comparison trials, a multi-stakeholder panel says at the annual Conference on Clinical Cancer Research.

Topics

UsernamePublicRestriction

Register

PS005750

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel